Potentiation of L-NAME-induced systemic and renal vasoconstrictor responses by α1-adrenoceptor antagonism

Journal of Hypertension

Volumn 23, Issue 5, 2005, Pages 1017-1024

  Van Der Linde, Nicole A J ^a   Boomsma, Frans ^a   Van Den Meiracker, Anton H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Blood pressure; Doxazosin; Losartan; NG nitro L arginine methyl ester; Renal vascular resistance; Systemic vascular resistance

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DOXAZOSIN; HYDROCHLOROTHIAZIDE; LOSARTAN; N(G) NITROARGININE METHYL ESTER; PLACEBO;

ADRENERGIC RECEPTOR BLOCKING; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; DEVICE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HUMAN; KIDNEY CLEARANCE; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 18344390875     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000166843.42227.92     Document Type: Article

References (29)

1. Baylis C, Qiu C. Importance of nitric oxide in the control of renal hemodynamics. Kidney Int 1996; 49:1727-1731.
2. Lahera V, Navarro-Cid J, Cachofeiro V, Garcia-Estan J, Ruilope LM. Nitric oxide, the kidney, and hypertension. Am J Hypertens 1997; 10:129-140.
3. Broere A, van den Meiracker AH, Boomsma F, Derkx FHM, Man in 't Veld AJ, Schalekamp MADH. Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME. Am J Physiol Renal Physiol 1998; 275:F870-F877.
4. Qiu C, Baylis C. Endothelin and angiotensin mediate most glomerular responses to nitric oxide inhibition. Kidney Int 1999; 55:2390-2396.
5. Montanari A, Biggi A, Carra N, Fasoli E, Calzolari M, Corsini F, et al. Endothelin-A blockade attenuates systemic and renal hemodynamic effects of L-NAME in humans. Hypertension 2000; 35:518-523.
6. Qiu C, Engels K, Baylis C. Angiotensin II and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. Am J Physiol Regul Integr Comp Physiol 1994; 266:R1470-R1476.
7. Qiu C, Engels K, Baylis C. Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J Am Soc Nephrol 1995; 6:1476-1481.
8. Ben Cheikh R, Feray JC, Alaoui A, Crozatier B. Thromboxane A2 in vasomotor effects of phenylephrine, acetylcholine, and bradykinin in rat mesenteric bed. J Cardiovasc Pharmacol 2002; 40:255-264.
9. Nafrialdi N, Jover B, Mimran A. Endogenous vasoactive systems and the pressor effect of acute N omega-nitro-L-arginine methyl ester administration. J Cardiovasc Pharmacol 1994; 23:765-771.
10. Montanari A, Tateo E, Fasoli E, Giberti D, Perinotto P, Novarini A, et al. Angiotensin II blockade does not prevent renal effects of L-NAME in sodium-repleted humans. Hypertension 1997; 30:557-562.
11. Turkstra E, Braam B, Koomans HA. Losartan attenuates modest but not strong renal vasoconstriction induced by nitric oxide inhibition. J Cardiovasc Pharmacol 1998; 32:593-600.
12. Van der Linde NAJ, Van den Meiracker AH, Boomsma F. Role of angiotensin II in L-NAME-induced systemic and renal hemodynamic effects in hydrochlorothiazide-pretreated hypertensive subjects. J Hypertens 2003; 21:345-351.
13. Baylis C, Engels K, Samsell L, Harten P. Renal effects of acute endothelial-derived relaxing factor blockade are not mediated by angiotensin II. Am J Physiol Renal Physiol 1993; 264:F74-F78.
14. Ortiz MC, Fortepiani LA, Ruiz-Marcos FM, Atucha NM, Garcia-Estan J. Role of AT1 receptors in the renal papillary effects of acute and chronic nitric oxide inhibition. Am J Physiol Regul Integr Comp Physiol 1998; 274:R760-R766.
15. Perinotto P, Biggi A, Carra N, Orrico A, Valmadre G, Dall'Aglio P, et al. Angiotensin II and prostaglandin interactions on systemic and renal effects of L-NAME in humans. J Am Soc Nephrol 2001; 12:1706-1712.
16. Huang F, Villafana S, Hong E. Role of central and sympathetic nervous systems in pressor effect of L-NAME. J Cardiovasc Pharmacol 2003; 41:68-72.
17. Sander M, Hansen J, Victor RG. The sympathetic nervous system is involved in the maintenance but not initiation of the hypertension induced by N(omega)-nitro-L-arginine methyl ester. Hypertension 1997; 30:64-70.
18. Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension 1999; 33:937-942.
19. van den Meiracker AH, van der Linde NAJ, Broere A, Derkx FHM, Boomsma F. Effects of L-arginine and L-NAME on the renal function in hypertensive and normotensive subjects. Nephron 2002; 91: 444-451.
20. Baylis C, Harvey J, Santmyire BR, Engels K. Pressor and renal vasoconstrictor responses to acute systemic nitric oxide synthesis inhibition are independent of the sympathetic nervous system and angiotensin II. J Pharmacol Exp Ther 1999; 288:693-698.
21. Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48:20-32.
22. Zietse R, Blankestijn PJ, Pos P, Balk AH, Derkx FM, Weimar W, et al. Optimising glomerular filtration rate and effective renal plasma flow measurements using a simple pharmacokinetic model. Clin Nephrol 1995; 43:29-34.
23. van der Hoorn FA, Boomsma F, Man in 't Veld AJ, Schalekamp MA. Determination of catecholamines in human plasma by high-performance liquid chromatography; comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr 1989; 487:17-28.
24. Derkx FH, Tan-Tjiong L, Wenting GJ, Boomsma F, Man in 't Veld AJ, Schalekamp MA. Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. Hypertension 1983; 5:244-256.
25. G-nitro-L-arginine as affected by blockade of pressor mechanisms mediated by the sympathetic nervous system, angiotensin, prostanoids and vasopressin. J Pharmacol Exp Ther 1992; 261:240-245.
26. Hirai T, Musch TI, Morgan DA, Kregel KC, Claassen DE, Pickar JG, et al. Differential sympathetic nerve responses to nitric oxide synthase inhibition in anesthetized rats. Am J Physiol Regul Integr Comp Physiol 1995; 269:R807-R813.
27. G-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo. A role for nitric oxide in the central regulation of sympathetic tone?. Circ Res 1992; 70:607-611.
28. Young RA, Brogden RN. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Drugs 1988; 35:525-541.
29. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283:1967-1975.